Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

r cell death and removal without resorting to chemotherapy.

About SPC2966

SPC2996 is the first of a portfolio of novel experimental drugs blocking harmful gene expression being designed and developed by Santaris Pharma. The drug belongs to a new class of drugs called RNA Antagonists, proprietary to Santaris Pharma, based on the novel three-dimensional analogue of RNA known as Locked Nucleic Acid (LNA). The drug binds with high potency and specificity to the messenger RNA for Bcl-2 and destroys it within the cell, resulting in a reduction in Bcl-2 protein concentration. SPC2996 is an investigational product which has not yet been approved by any regulatory agency as effective or safe for patient use but the novel agent is currently being evaluated in international Phase I/II studies in human CLL in centres in Denmark, France, UK and the USA.

About Santaris Pharma

Santaris Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of drugs intended to switch off the expression of harmful genes. Called RNA Antagonists, these new drugs are being developed by Santaris and its corporate partners for the treatment of cancer and metabolic disorders. Created in May 2003 and backed by a broad group of leading international life science venture capital investors, Santaris Pharma completed a Euro 40m second round of equity financing in May 2006. In July 2006, the Company entered into a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris RNA Antagonists for improving the treatment of cancer.

Santaris Pharma's RNA Antagonist drug pipeline is based on its unique LNA technology. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the u
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
(Date:11/24/2014)... Pa. , Nov. 24, 2014  Inovio Pharmaceuticals, Inc. ... J. Joseph Kim , President and CEO of Inovio Pharmaceuticals, ... management team to ring the Nasdaq Opening Bell tomorrow, Tuesday ... Inovio,s September 15 th listing on the Nasdaq Global ... ceremony, Dr. Kim said, "We are honored to ring the ...
(Date:11/22/2014)... 2014  New data demonstrates that flibanserin, a novel, ... of female sexual dysfunction, Hypoactive Sexual Desire Disorder (HSDD), ... in premenopausal women when taken at bedtime. The data ... North America,s (SMSNA) 20th Annual Fall ... SMSNA accepted this study as a late ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3
... The National,Comprehensive Cancer Network (NCCN) announces updates to ... Cancer,and Gastric Cancer. The NCCN Guidelines are updated ... recognized and,applied as the standard of care in ... and the academic practice settings., In response to ...
... of the Most Challenging Patient Populations,Studied of Any ... PARK, Calif., May 22, 2007,/PRNewswire-FirstCall/ -- XTENT, Inc. ... clinical trial, which assessed,the safety and efficacy of ... for the treatment of long and,multiple lesions in ...
Cached Medicine Technology:NCCN Updates Esophageal and Gastric Cancer Guidelines 2NCCN Updates Esophageal and Gastric Cancer Guidelines 3XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 2XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 3XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 4
(Date:11/24/2014)... 24, 2014 Gersowitz Libo & Korek, P.C., ... received national Tier recognition in the 2015 Edition of U.S. ... ranking signals a unique combination of quality law practice and ... receive this honor and especially grateful to our clients whose ... and ranking possible,” said Jeff S. Korek, senior partner at ...
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has unveiled ... They are now offered at deeply discounted prices, up ... now to Dec. 15. The main purpose of the promotion ... high quality items are ideal options for ladies who are ... money. All its new mint cocktail dresses are very beautiful; ...
(Date:11/23/2014)... November 23, 2014 Pro Ace Care, a ... it will now be providing an 8 year warranty on ... water tank installations went up due to the impending winter ... its customers of the premium service that the company provides. ... year warranty on John Wood and Bradford hot water tanks. ...
(Date:11/23/2014)... 2014 Locks-Magnetic.com, a notable magnetic locks ... all the new products are available at low rates ... is proud of the new emergency doors. The emergency ... customers can choose from several colors. All of the ... emergency door release is not as easy as many ...
(Date:11/23/2014)... More than two dozen new claims ... litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well ... reports. , A Case List updated on November ... Type 2 diabetes medications referred to as incretin mimetics ... Southern District of California, where a federal proceeding continues ...
Breaking Medicine News(10 mins):Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... after women have separated from an abusive partner, the violence still ... at the University of British Columbia. Led by UBC Nursing ... of Canadian Public Policy is the first in ... used by women who leave a violent partner. Overall, ...
... and Reinvestment Act award from the Agency for Healthcare ... Indiana Network for Patient Care (INPC), the nation,s largest ... simultaneously supports a groundbreaking comparative effectiveness research study using ... harms of three drugs commonly used to treat Alzheimer,s ...
... A pioneering international collaboration forged by Fred Hutchinson ... with the Uganda Cancer Institute in Kampala, Uganda, ... a state-of-the-art cancer training and outpatient treatment facility ... comprehensive cancer center jointly constructed by U.S. and ...
... by University of Cincinnati (UC) faculty members shows that ... clinical experience helps internal medicine residents improve their scores ... findings, published in the advance online edition of the ... print in November, validate the benefit of this and ...
... of 606 Canadian physicians were disciplined by their provincial ... St. Michael,s Hospital found. The majority of disciplined ... practicing medicine for a long time (an average of ... according to Dr. Chaim Bell. The most frequent ...
... wild, poisonous mushroom growing in a Southwest China forest appears ... report. , The compound, verticillin A, sensitizes cancer cells to ... said Dr. Kebin Liu, cancer immunologist at the Georgia Health ... in the journal Cancer Research . , The compound ...
Cached Medicine News:Health News:Annual cost of violence pegged at $6.9 billion after women leave abusive partners, UBC research 2Health News:$8.4 million grant supports health information exchange and research on Alzheimer's drugs 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 3Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 4Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 5Health News:New testing program improves scores, knowledge retention for third-year internal medicine residents 2Health News:New testing program improves scores, knowledge retention for third-year internal medicine residents 3Health News:Researchers track number of doctors disciplined and why 2Health News:Mushroom compound appears to improve effectiveness of cancer drugs 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: